LINCOLNBSELincoln Pharmaceuticals LtdLowNeutral
Announced Mon, 18 May · 14:36 IST

Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve Audited (standalone ....

LINCOLN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+10.8%1-day move
₹643.50
prior close
₹634.90
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.9+3.0+4.0+5.8+10.8+10.5+14.2+13.8+12.2+18.1-1.2-5.0-7.7
Up moveDown movePending
AI summary

Lincoln Pharmaceuticals Ltd has informed exchanges that a Board meeting is scheduled for May 28, 2026. The meeting will consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board will also consider recommending a dividend on equity shares, if any. The company has closed its trading window from April 01, 2026, which will reopen after 48 hours from when the results become generally available. This is a routine pre-result board meeting intimation filed under SEBI Listing Regulations.

Likely market impact

This is a standard board meeting notice announcing the upcoming Q4/FY results date. The dividend consideration is a positive signal for shareholders, though the actual outcome will be known only after the meeting. No specific financial data or audit opinions are disclosed in this filing.